We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Journal Articles

in Cancer Biomarkers

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Invited Commentary  | 
PD-L1 Expression as a Predictive Biomarker Is Absence of Proof the Same as Proof of Absence?
Feriyl Bhaijee, MD; Robert A. Anders, MD, PhD
JAMA Oncology
Viewpoint  | 
PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development
Aaron R. Hansen, MBBS (Hons), FRACP; Lillian L. Siu, MD
JAMA Dermatology
Original Investigation  | 
The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma
Rui Xu, BS; Mu-Yan Cai, MD; Rong-Zhen Luo, MD; et al.
JAMA Oncology
Original Investigation  | 
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Chau Dang, MD; Hao Guo, MS; Julie Najita, PhD; et al.